Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in ...
Vivani Medical Announces $8.25M Private Placement Equity Financing
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated ...
TMCnet7d
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
CNBCTV188d
Exclusive | Eli Lilly's Global CEO David Ricks says might make Mounjaro in India
GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...
IFLScience9dOpinion
Some Science Is Easy To Mock, But It Might Have Saved Your Life
Just because a research project sounds like a waste of money to people who know nothing of the topic, doesn’t mean it won’t ...
Benzinga.com21d
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
Vivani also expects the results to support the potential application of a GLP-1 (exenatide) implant for type 2 diabetes and other diseases. How to Spot the Market Bottom: Matt Maley has navigated ...